Fig. 6
From: Single protein encapsulated SN38 for tumor-targeting treatment
Mean TV and % BW change vs treatment time, tumor weight for SPESN38-5 and irinotecan. A Mean TV vs treatment time for all female mice. Mice # for each group, control (n = 8), SPESN38-5, PO (n = 8), Irinotecan (n = 6), and SPESN38-5, IV (n = 8). On Day 10, SPESN38-5, PO, TGI, 24.1%, very significantly lower than control group (***, p = 0.00022), Irinotecan, TGI, 82.3%, very significantly lower than control group (***, p < 2 × 10–16), SPESN38-5, IV, TGI, 96.6%, very significantly lower than control group (***, p < 2 × 10–16), SPESN38-5, IV significantly reduced tumor volume, compared to Irinotecan group (*, p = 0.0241). On Day 21, SPESN38-5, IV, very significantly reduced tumor volume, compared to Irinotecan group (***, p = 1.6 × 10–5); B % BW change vs treatment time for all mice, not significantly different from each other, SPESN38-5 PO group did not display any BW loss; C Comparison of the average tumor weights at their ending points